Business Context and Reporting Period
This Form 8-K Current Report was filed by Relmada Therapeutics, Inc. on November 6, 2015, covering events occurring on November 6, 2015, and November 12, 2015. The filing addresses changes to the Company's Board of Directors, including the resignation of one director and the appointment of two new directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director compensation arrangements.
- Director Compensation (Maged Shenouda): $30,000 annual retainer plus $6,000 annual Audit Committee fee.
- Director Compensation (Paul Kelly): $30,000 annual retainer plus $5,000 annual Compensation Committee fee.
- Equity Grants: Both new directors received 25,765 stock options each with a 10-year term and an exercise price based on the share price on November 12, 2015.
Material Changes
The primary material change reported is the composition of the Board of Directors:
- Resignation: Dr. Nabil Yazgi resigned from the Board of Directors, as well as the Audit and Compensation Committees, effective November 6, 2015, to pursue other interests.
- Appointments: On November 12, 2015, the Board appointed Maged Shenouda (Class I Director) and Paul Kelly (Class III Director).
- Committee Assignments: Mr. Shenouda joined the Audit and Compensation Committees. Mr. Kelly joined the Compensation Committee.
Outlook, Risks, and Unusual Items
The filing does not contain financial guidance, market outlook, or specific risk factors. The Company highlighted the extensive biotechnology experience of the new directors as a strategic asset:
- Maged Shenouda: Over 25 years of biotechnology and equity research experience, including roles at Retrophin, Blueprint Life Science Group, Stifel Nicolaus, UBS, and JP Morgan.
- Paul Kelly: Over 20 years of experience as an analyst, consultant, and investor in the biotechnology sector, with a background at UBS, Merrill Lynch, and ING Securities.
Both new directors entered into Indemnity Agreements with the Company.
Investor Verification Checklist
- Verify the exact share price on November 12, 2015, to determine the exercise price of the 51,530 total options granted to the new directors.
- Confirm the total number of outstanding shares to assess the dilution impact of the new option grants.
- Review the full text of the Director Agreements (Exhibits 10.1 and 10.3) for any additional compensation terms or termination clauses not summarized in the 8-K.
- Check subsequent filings to confirm shareholder approval of the new directors at the 2015 annual meeting.